CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support

▤ Summary

CONNECTA Therapeutics announced that it will advance CTH120 into pediatric Phase II development for Fragile X syndrome after positive Phase I results. The company secured a 2.5 million euro EIC Accelerator grant to support regulatory, preclinical, and formulation work for the program. CONNECTA plans to submit its Pediatric Investigation Plan and prepare the trial path for pediatric patients, while also continuing adult Phase IIb planning. The company positions CTH120 as a first-in-class disease-modifying therapy that targets TrkB and neuroplasticity in central nervous system disorders.

$ Funding

▦ Linked Companies